THE AMENDMENT

In The Claims

1. (Currently Amended) A method for treating ~~cognitive disorders or mnestic disorders which accompany CNS diseases~~ schizophrenia, comprising administering to a patient the *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8.

2-5. (Cancelled)

6. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically effective dose of the *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8, or one of its pharmaceutically acceptable salts, in admixture with a pharmaceutically acceptable carrier.

7. (Cancelled)

8. (Currently Amended) A *R*(+)-2-amino-3-hydroxypropanoic acid derivative of formula III, or one of its pharmaceutically acceptable salts;



(III)

wherein R is [[a]] hydrogen;

R' is [[a]] hydrogen, or a phenyl(C_2-C_6)alkenyl group, or a gem-diphenyl(C_1-C_6)alkyl group other than benzhydryl, or a gem-diphenyl(C_2-C_6)alkenyl group; or

R and R', together, form a phenyl(C_1-C_6)alkylidene or gem-diphenyl(C_1-C_6)alkylidene group;

R" is [[a]] hydrogen or a (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl(C_1-C_6)alkyl, phenyl(C_1-C_2)alkyl or phenacetyl group;

the phenyl group or groups being non-substituted or substituted by a halogen atom or by a hydroxy, (C_1-C_3)alkoxy, cyano, nitro or acetyl group;

with the proviso that, when R and R' are both hydrogen, then R" is other than [[a]] hydrogen, (C_1-C_6)alkyl or non-substituted benzyl.

9. (Previously Presented) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to claim 8, where R' is a ω-diphenyl(C_2-C_6)alkyl group.

10. (Original) *R*(+)-N-(4,4-diphenyl)butyl-2-amino-3-hydroxypropanoic acid or a pharmaceutically acceptable salt thereof.

11. (Original) *R*(+)-N-[(4,4-diphenyl)-3-butenyl]-2-amino-3-hydroxypropanoic acid or a pharmaceutically acceptable salt thereof.

12. (Original) *R*(+)-N-[α-phenyl-(2-hydroxy)benzylidene]-2-amino-3-hydroxypropanoic acid or a pharmaceutically acceptable salt thereof.

13. (Previously Presented) The method according to claim 1, wherein said treatment increases glycinergic transmission in said patient.

14. (Previously Presented) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to claim 8, wherein R' is a phenyl(C_2-C_6)alkenyl.

15. (Previously Presented) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8, which is R(+)-N-(4,4-diphenyl)butyl-2-amino-3-hydroxypropanoic acid hydrochloride.

16. (Currently Amended) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8, which is <u>methyl</u> R(+)-N-[(4,4-diphenyl)-3-butenyl]-2-amino-3-hydroxypropanoate.